Overview

Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relapse Prevention

Status:
RECRUITING

Trial end date:
2028-10-30

Target enrollment:

Participant gender:

Summary

This study is a prospective, phase II clinical trial with the primary objective of assessing the effectiveness of demethylating agents combined with venetoclax in the prevention of recurrence after allogeneic hematopoietic stem cell transplantation (allo-HSCT) of high risk T-lymphoblastic lymphoma/leukemia (T-LBL/ALL) patients.

Phase:

PHASE2

Details

Lead Sponsor:

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Treatments:

Azacitidine
Decitabine
venetoclax